Image

Improving Diagnosis and Prediction of Outcome in Patients With Severe Disorders of Consciousness

Improving Diagnosis and Prediction of Outcome in Patients With Severe Disorders of Consciousness

Recruiting
18 years and older
All
Phase N/A

Powered by AI

Overview

Patients with acute severe brain injury are usually admitted to the Intensive Care Unit. A substantial proportion of these patients will have disorders of consciousness (DOC) after interruption of sedation. It is difficult to reliably predict neurological outcome in these patients. Dependent on the extent of permanently damaged brain areas, DOC in patients with acute severe brain injury may improve or persist, eventually evolving into a minimal conscious state (MCS) or unresponsive wakefulness syndrome (UWS). These conditions are accompanied by long term severe disability. In current practice, the decision to withdraw life-sustaining support is made by interpreting the results of repeated bedside neurological examination and conventional CT-brain imaging. Reliable identification of patients with a possible good outcome, in whom treatment should not be withdrawn, is difficult. In this prospective observational cohort study we aim to identify patients with a good neurological outcome.

Description

In order to identify patients with a good neurological outcome a combination of diagnostic tests is used.

Clinical rating scales

  • Simplified evaluation of consciousness scale (SECONDs) and the full outline of unresponsiveness (FOUR) score
  • Once a week

Blood biomarkers

  • Neuron specific enolase, neurofilament light, glial fibrillary acidic protein
  • Sampling timepoints: 24h, 72h, 7 days and 14 days after brain injury
  • Serum (STG-5) and plasma (EDTA-6) tubes, aliquoted (4 x 0.5ml) and stored at -80°C

EEG with reactivity testing

  • Standard 21-electrode montage
  • Stimuli protocol I: a set of 5 stimuli repeated 3 times
    1. Auditory: clapping in hands, 2. Auditory: calling patients name loudly, 3. Visual: passive eye opening, 4. Tactile: nasal tickle, 5. Noxious: sternal rub Each stimuli is applied for a duration of 5 seconds and an interval between stimuli of 30 seconds
  • Stimuli protocol II: Cognitive-motor dissociation test

MRI-scan

  • Sequences considered essential for patient care i.e.T1, T2, FLAIR, DWI/SWI
  • Preferably, performed between 4-6 weeks after hospital admission

Eligibility

Inclusion Criteria:

All patients that are admitted to the ICU with the following criteria will be eligible for inclusion:

  1. Severe brain injury (GCS ≤ 8) as a result of:
    1. Traumatic brain injury
    2. Ischemic cerebrovascular accident
    3. Intracranial hemorrhage
    4. Meningo-encephalitis
    5. Subarachnoid hemorrhage
  2. Age ≥ 18 years old
  3. Written informed consent from legal representatives

Exclusion Criteria:

A potential subject who meets any of the following criteria will be excluded from participation in this study:

  • Absence of informed consent
  • Moribund at ICU admission
  • Progressive neurodegenerative disease
  • Pre-admission life expectancy ≤ 6 months based on comorbidity
  • GCS has been > 8 prior to inclusion
  • Impossible to include within 24 hours after brain injury

Study details
    Traumatic Brain Injury
    Intracranial Hemorrhages
    Subarachnoid Hemorrhage
    Meningitis
    Encephalitis
    Stroke

NCT06283901

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

21 October 2025

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.